All In Biotech

Drug Trial Radar · NCT00303056

Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis

Efficacy and Safety of Intra-articular Multiple Doses of 500 µg Icatibant Including 40 mg Triamcinolone as Calibrator in a Randomized, Double-blind, Parallel-group, Placebo-controlled 13-week Multi-centre Study in Patients With Symptomatic Knee Osteoarthritis

Last checked: Nov 20, 2026Latest source record: Feb 17, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

590

Actual

Start

Feb 2006

Primary completion

Jul 2007

Study completion Jul 2007

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 15, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to compare the overall treatment effect on pain relief between icatibant and placebo. The secondary objectives are to assess the efficacy of icatibant in term of onset, extent and duration of pain relief relative to triamcinolone, to evaluate the safety of icatibant, to evaluate overall conditions of daily life after treatment with icatibant, to assess systemic exposure of icatibant following intra-articular injection.

Conditions

  • Joint Disease

Interventions

  • HOE140 IcatibantDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain during activity, at rest and at night will be measured daily via an electronic patient diary (EPD) using a 100-unit visual analog scale (VAS).

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • Administrative Office

    Bridgewater, New Jersey

  • Administrative Office

    Vienna, Austria

  • Administrative Office

    Prague, Czechia

  • Administrative Office

    Berlin, Germany

  • Administrative Office

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.